HPVE6/E7mRNA联合液基薄层细胞学检测在宫颈癌筛查中的应用价值

Application Value of Hpve6/E7 mRNA Combined With Thinprep Cytology in Cervical Cancer Screening

目的观察HPVE6/E7mRNA联合液基薄层细胞学检测(TCT)在宫颈癌筛查中的应用价值分析。方法选取2019年6月至12月收治于我院进行HPVE6/E7mRNA与液基薄层细胞学检测(TCT)检查的宫颈癌筛查者100例,筛查者也接受经阴道镜下活检项目,以活检结果为最终诊断的"金标准",分析单独检测对疾病诊断的准确率及联合检测的诊断结果。结果 "金标准"中,42例炎症(42.00%),26例CIN I(26.00%),10例CIN Ⅱ(10.00%),18例CIN Ⅲ(18.00%),4例宫颈癌(4.00%)。这其中不同类型者年龄、性生活史比较,差异无统计学意义(P>0.05)。随着疾病严重程度的增加,单独检测的诊断准确率也随之升高,差异(P<0.05)有统计学意义。结论在宫颈癌筛查中的应用HPVE6/E7mRNA、液基薄层细胞学检测,单一检查时恶性程度越高,诊断准确率越高,而实施联合检测,可以获得较高的灵敏度,可以作为宫颈癌筛查的检测的选择方案,为早期的干预提供临床依据。

Objective To observe application value of HPVE6/ E7 mRNA combined with Thinprep cytology (TCT) in cervical cancer screening.Methods We chose 100 cases of cervical cancer screening patients with hpve6/E7 mRNA,liquid-based thin-layer cytology (TCT) examination and colposcopic biopsy in our hospital from June to December 2019.With the biopsy results as "gold standard" of final diagnosis,analyzed the accuracy rate of single and combined detection for disease diagnosis.Results In "gold standard",there were 42 cases of inflammation (42.00%),26 cases of CIN I (26.00%),10 cases of CIN II (10.00%),18 cases of CIN III (18.00%),4 cases of cervical cancer (4.00%),there was no significant difference in age and sexual life history among different types of patients (P>0.05).With increase of disease severity,diagnostic accuracy of single detection increased,difference was significant (P<0.05).Conclusion HPVE6/E7mRNA and liquid-based thin-layer cytology each can achieve higher diagnostic accuracy of malignancy in cervical cancer screening,and combined detection can obtain higher sensitivity,which can be be selection scheme of cervical cancer screening and provide clinical basis for early intervention.